ANI Pharmaceuticals (ANIP)

[Just the facts maam]

In researching the patent application process, it appears that ANI will have to petition to revive the patent applications. It also appears that this should be done within three months of receiving notification of the abandonment, otherwise they risk a greater chance of the petition being denied.

The fact ANI paid the required fees without submitting a response to the last office action is indicative of something else being in the works. It also signals to the examiner that they, or another partie, intends to continue prosecuting the patent application. Otherwise, why pay the extension of time fee?

The fact that both the Commercial Scale Production and the CV Risk Reduction patent applications are in a status of Abandonment for Failure to Respond to an Office Action with both having fees to extend time paid up and granted, increases the possibility that the patents have been re-assigned, at least partially, to a third party or that the next submission could point to a partnership, that they are not ready to announce.

If, as I suspect, Abbvie is the partner, the FDA approving Amgen's Amjevita as a biosimilar for Humira on September 23, 2016 and J&J's Guselkumab outperforming Humira for treating psoriasis in clinical trials, may be the driving force to get Libigel or whatever it will be called moving, even while they work to secure patents. In the meantime they do have the patent protection assigned to Antares for testosterone restoration.

Guselkumab

Amjevita

Antares patent